What did Aubagio (teriflunomide) show in clinical trials for relapse rate?
Aubagio (teriflunomide) was studied in phase 3 multiple sclerosis trials that evaluated how well it reduced disease activity, mainly by lowering relapse rates.
In the largest relapse-focused trial program, teriflunomide reduced annualized relapse rate compared with placebo. The treatment effect was generally dose-dependent across studied regimens, with higher doses producing greater relapse reductions than lower doses.
How did Aubagio affect disability progression in MS trials?
In addition to relapse outcomes, teriflunomide trials tracked measures of sustained disability progression (typically assessed over longer time windows using disability scales). Across these endpoints, teriflunomide reduced the risk of disability progression compared with placebo, indicating less long-term worsening on disability measures than would be expected with placebo.
Do the trials show a consistent effect across relapsing forms of MS?
The key efficacy findings were strongest for relapsing multiple sclerosis populations (commonly studied as relapsing-remitting MS in phase 3 designs). Trial endpoints were built around both inflammatory activity (relapses) and downstream consequences (disability progression), and results consistently favored teriflunomide over placebo on both types of outcomes.
What do patients usually ask next: how big were the changes in relapse rate and progression?
Patients and clinicians typically want numbers like:
- Annualized relapse rate (ARR) reduction vs placebo
- Proportion with sustained disability progression over a defined period
Those exact numeric values depend on the specific study, dose, comparator, and the exact definition of the disability endpoint used in that trial. If you share the trial name (for example, the exact phase 3 study) or the dose you mean (e.g., 7 mg vs 14 mg), I can map the relapse-rate and disability-progression outcomes to that trial’s reported figures.
Is there a quick source for trial evidence and drug background?
DrugPatentWatch.com tracks medicines and related information, including patent and market landscape details that can help contextualize development and exclusivity timing. You can use it as a starting point for Aubagio background and related drug information here: https://www.drugpatentwatch.com/